Journal of Addiction Medicine · 2015 · 17 citations · 19 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPediatric Clinical PharmacologySubstance Use DisordersAdolescent PharmacotherapyOpioid PharmacologyOpioid Use Disorder12-Lead ElectrocardiographyBuprenorphine TreatmentPartial Agonist EfficacyPartial Agonist PotencyQt Interval AssessmentRandomized Controlled Trial Baseline
OBJECTIVES: The aim of the study was to evaluate buprenorphine-naloxone effects on the QTc in youth with opioid dependence. Buprenorphine is a partial agonist that is an effective treatment for opioid dependence. Compared with methadone, it has a lower risk of QTc prolongation in adults, but is less studied in the youth. It may also reduce the risk of torsades de pointes (TdP)--an uncommon variant of polymorphic ventricular tachycardia--that can result in syncope, ventricular fibrillation, and sudden death. METHODS: Secondary analysis of the electrocardiogram data from 95 individuals who participated in a multisite trial for youth with opioid dependence. The participants were randomized to a 2-week (DETOX) or a 12-week course of buprenorphine-naloxone (BUP). At baseline, 12-lead electrocardiograms were done at weeks 4 and 12, and QTc intervals were hand-measured and calculated using Bazett formula. Increases above 60 milliseconds were considered clinically significant, and readings above 450 milliseconds (in men) and 470 milliseconds (in women) indicated a prolonged QTc. RESULTS: Mean QTc intervals were higher for BUP than for DETOX participants at baseline, week 4, and week 12 (P = 0.045), and women had longer mean QTc intervals than men (P < 0.0005). Variations in the QTc intervals were observed in some; however, none were above 500 milliseconds--the level at which risk for TdP becomes more significant. CONCLUSIONS: In this randomized trial, the mean QTc at baseline, before randomization, was higher in BUP than in DETOX patients. Minimal changes in the QTc were seen at 4 and 12 weeks in a few patients in both groups. There was no evidence that buprenorphine-naloxone alone increased the QTc to a level that increased the risk for TdP.
19
Risk Stratification in the Long-QT Syndrome
Silvia G. Priori, Peter J. Schwartz, Carlo Napolitano et al. · New England Journal of Medicine · 2003 · 1.4K citations · Full text
Torsade de Pointes Associated with Very-High-Dose Methadone
Mori J. Krantz, Laurent Lewkowiez, Helen Hays et al. · Annals of Internal Medicine · 2002 · 424 citations
Andrew J. Sauer, Arthur J. Moss, Scott McNitt et al. · Journal of the American College of Cardiology · 2007 · 413 citations
Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth
George Woody, Sabrina Poole, Geetha Subramaniam et al. · JAMA · 2008 · 358 citations · Full text